Skip to main content

Table 3 Baseline demographic, clinical and serological characteristics of the 192 patients subdivided according to diagnosis after 24 months

From: Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study

Parameter at onset Patients developing RA Patients not developing RA P
  Number % Number %  
Patients 72 37.5 120 62.5  
Age, years, mean ± SD 52 ± 16 na 52 ± 15 na 0.895
Female 57 79.2 90 75.0 0.628
Monoarthritis 7 9.7 11 9.2 0.999
Oligoarthritis 16 22.2 41 34.2 0.111
Polyarthritis 49 68.1 68 56.6 0.158
Hand joints arthritis 55 76.4 71 59.2 0.023
CRP+ 41 56.9 58 48.3 0.314
CRP ratio, median (IR) 1.9 (0.6-1.9)   0.9 (0.6-2.6)   0.031
ESR increase 38 52.8 65 54.2 0.970
ESR median (IR) 24 (12.3-53.3)   22.5 (16.0-38)   0.773
RF+ 45 62.5 34 28.3 < 0.0001
RF ratio, median (IR) 2.3 (0.6-7.8)   0.6 (0.5-1.2)   < 0.0001
RF low+/total RF+ 11 24.4 15 44.1 0.109
RF high+/total RF+ 34 75.5 19 55.9  
ACPA+ 53 73.6 27 22.5 < 0.0001
ACPA ratio, median (IR) 5 (0.6-14.3)   0.5 (0.3-0.8)   < 0.0001
ACPA low+/total+ 7 13.2 6 22.2 0.476
ACPA high+/total+ 46 86.8 21 77.8  
RF+/ACPA- 2 2.8 12 10 0.115
RF-/ACPA+ 10 13.9 5 4.2 0.031
RF+/ACPA+ 43 59.7 21 18.3 < 0.0001
RF-/ACPA- 17 23.6 81 67.5 < 0.0001
  1. RA, rheumatoid arthritis; CRP, C-reactive protein; IR, interquartile range; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies; NA, not applicable.